GLP-1 and Muscle Loss: What the Research Actually Shows
“Will I lose muscle on a GLP-1?” It’s one of the most important questions in weight loss medicine right now. It’s also one of the worst-served by the internet. Search it, and the topic of GLP-1 muscle loss throws confident answers at you in both directions. One camp says don’t worry about it. The other says these drugs waste your muscle away. As a physiotherapist, I find both frustrating, because the real research is more nuanced, more interesting, and genuinely more useful once you understand it.
So let’s go through it properly. Here’s what we’ll cover: what these medications actually do inside your body, right down to the cellular level; what the trials measured about GLP-1 muscle loss and lean mass; why muscle matters so much when you’re losing weight; and what you can actually do about it. Every number here comes straight from the original research, no secondhand figures, no game of telephone. This is my independent read of the science, written to inform you, not to sell you anything.
What Are GLP-1 Medications, Exactly?
GLP-1 stands for glucagon-like peptide-1. It’s a hormone your gut releases naturally after you eat. Scientists call it an incretin, a technical word for a messenger molecule that helps your body respond to a meal. It nudges your body to release insulin, and it tells your brain you’re full. There’s one catch: natural GLP-1 falls apart within minutes. That made it useless as a medicine on its own.
The breakthrough was building GLP-1 receptor agonists. (An agonist is simply something that switches a receptor on.) These are lab-made molecules that copy GLP-1 but resist the enzyme that normally breaks it down, so instead of lasting minutes, they keep working for days.1 Semaglutide, the molecule in Ozempic and Wegovy, is the best known. Tirzepatide (in Mounjaro and Zepbound) goes one step further. It flips two switches instead of one: the GLP-1 receptor, plus a second one called GIP.2 That double action is part of why its trial numbers run higher, as we’ll see.
One thing worth flagging early: these molecules were first developed for type 2 diabetes. The weight-loss effect showed up along the way. Everything below describes how the molecules themselves behave, semaglutide and tirzepatide as they were studied in the published trials, which used the FDA-approved branded products. Hold onto that distinction. It matters later.
How GLP-1 Medications Work at a Cellular Level
This is the part most articles skip. It’s also the part that explains everything else, so stay with me. It’s genuinely elegant once it clicks, and I’ll use a simple picture to get us there.
Picture one of your cells as a house. On the outside wall sits a doorbell, that’s the GLP-1 receptor. (Scientists call it a G-protein coupled receptor, but “doorbell” will do just fine.) These doorbells sit on cells all over your body: pancreas, gut, and brain among them.3 When a GLP-1 molecule, or a drug copying it, presses that doorbell, it doesn’t do the work itself. It sets off a chain reaction inside the house. Here’s that chain, one step at a time:
The drug locks onto the receptor and changes its shape. Just inside the wall, that wakes up a messenger protein (called a G-protein, or Gαs) waiting behind the door.3,4
That messenger switches on a tiny machine, an enzyme called adenylyl cyclase. The machine rapidly pumps out a substance called cAMP. Think of cAMP as the cell’s internal loudspeaker, shouting “message received, act now” to the whole room.3,4
The rising cAMP loudspeaker flips two switches at once, two worker proteins named PKA and Epac2. Their job is to turn that “act now” signal into real action inside the cell.3,4
In the insulin-making cells of the pancreas, those workers release insulin. But here’s the clever part: they only do it when your blood sugar is already high. If your sugar is normal, nothing gets forced out. That built-in safety catch is why these drugs, on their own, rarely push blood sugar too low.3,5
That insulin effect is how these drugs treat diabetes. But it’s not what drives weight loss. For that, we need to look at the brain.
How GLP-1 Medications Act on the Brain to Reduce Appetite
This is where the weight loss actually comes from, and it’s more about the brain than the belly. Those same GLP-1 doorbells sit in the brain regions that control hunger and fullness. And the drugs reach them.
Your brain is normally sealed off by a protective wall (the blood-brain barrier). But that wall has a few gates where it’s naturally thinner. Research tracking these molecules shows they slip in through those gates, landing mainly in two hunger-control hubs deep in the brain.6,7 (For the curious: the main ones are the brainstem’s dorsal vagal complex and the hypothalamus’s arcuate nucleus.) Once inside, the drug works on two opposing teams of brain cells:
| Brain-cell team | What GLP-1 does to it | Net effect |
|---|---|---|
| POMC / CART neurons | Switches them on, these are the “fullness” cells | Signals you’re satisfied |
| AgRP / NPY neurons | Quiets them down, these are the “hunger” cells | Turns down the drive to eat |
And this isn’t just theory. Studies on human brain cells grown in the lab confirm that our “fullness” cells carry the GLP-1 doorbell and respond to semaglutide.7 Animal studies show the appetite effect runs through the same cAMP loudspeaker we met earlier.6 The real-world result is what many people call less “food noise.” That constant background pull toward eating quietens down. You feel full sooner, and you stay full longer.
There’s a gut effect too. GLP-1 slows how fast your stomach empties, so food sits there longer and you feel satisfied for longer after a meal.1 Put the brain effect and the slower stomach together, and you simply eat less. Eating less, consistently, is what drives the weight loss. Tirzepatide adds its second switch (GIP) on top of all this, which is thought to explain its bigger effect in trials.2
What the Clinical Trials Actually Showed
The results behind these medications are, frankly, unlike anything obesity medicine had before. Here are the headline numbers, each taken straight from the original trial:
| Trial | Medication | Average weight lost | Over |
|---|---|---|---|
| STEP 18 | Semaglutide 2.4 mg | 14.9% | 68 weeks |
| SURMOUNT-19 | Tirzepatide (up to 15 mg) | Up to 20.9% | 72 weeks |
| SURMOUNT-510 | Tirzepatide vs semaglutide (head-to-head) | 20.2% vs 13.7% | 72 weeks |
In the STEP 1 trial, weekly semaglutide led to an average weight loss of 14.9%. Most participants, 86% of them, lost at least 5% of their body weight.8 SURMOUNT-1 raised the ceiling, with tirzepatide reaching up to 20.9% at its highest dose.9 Then in 2025, SURMOUNT-5 put the two drugs head-to-head for the first time. Over 72 weeks, tirzepatide came in at 20.2% versus semaglutide’s 13.7%.10
Two honest caveats I’d flag as a physiotherapist. First, these are averages, and the trials paired the drug with lifestyle support. Individual results vary hugely, and the medication is never the whole story. Second, and this is the crux of the article, total weight lost is not the same as fat lost. To see what’s happening to your muscle, you have to look underneath that headline number.
The GLP-1 Muscle Loss Question: What the Evidence Shows
Now to the heart of it. When you lose weight, that weight comes off in more than one form. Some of it is fat. Some of it is what’s called lean mass, a category that includes muscle, but also water, organ tissue, and more. This happens with nearly every weight-loss method, from plain dieting to weight-loss surgery. It is not unique to GLP-1 drugs.
So how much of the loss is lean mass? A widely-cited 2024 review by Prado and colleagues, published in The Lancet Diabetes & Endocrinology, put it at roughly 25 to 39% of total weight lost across medically-driven weight-loss studies.11 That’s a real share, and it’s the figure many clinicians quote. But it needs careful reading, and here I’d rather be precise than alarming.
So here’s the fair summary. Lean mass loss during GLP-1 weight loss is real and measurable. The reported size of that GLP-1 muscle loss swings widely depending on the study and how it was measured. And some of it isn’t permanent muscle at all. The question that actually matters isn’t “does it happen”, it does, with any weight loss. It’s “does it matter, and can you do anything about it?” On both counts, the answer is yes.
Why Lean Mass Matters When You Lose Weight
This is where my physiotherapy background makes me care more than the average weight-loss blog. Muscle isn’t just about strength or looks. It’s living, active tissue, and it shapes how your body works both during and after weight loss.
The clearest link is to your resting metabolism: the calories you burn just existing, before any exercise. Muscle is one of the biggest drivers of that number.12 The logic is simple. Lose a meaningful chunk of muscle, and your resting burn can drop. A lower resting burn makes it harder to keep the weight off once treatment ends. Muscle also keeps you strong and mobile, helps your body manage blood sugar, and, especially as we age, protects against frailty.
This links directly to one of the most sobering findings in the whole GLP-1 field: what happens when people stop. In the STEP 1 follow-up, people who came off semaglutide regained about two-thirds of their lost weight within a year.13 The SURMOUNT-4 trial found the same pattern with tirzepatide.13 I’ve written a separate deep-dive on that, the weight-regain research is worth reading in full, but the piece that matters here is body composition. If you finish a weight-loss phase carrying less calorie-burning muscle, the odds may be tilted toward regain. Protecting muscle isn’t about vanity. It’s part of keeping the weight off.
What the Evidence Says About Protecting Muscle
Now the genuinely good news, the part you control. The research agrees on two simple levers that help you hold onto muscle while you lose weight. Neither one is exotic.
Strength training
Strength training is the single most reliable way to protect muscle while you’re eating less. A landmark trial by Villareal and colleagues, in older adults with obesity, found that combining strength and cardio during weight loss best preserved both muscle and physical function.14 The reason is intuitive: muscle responds to demand. Give it a regular reason to stick around, lifting, resistance, loading, and your body is far less willing to burn it for fuel. In my practice, this is the highest-value thing anyone losing weight can do.
Enough protein
Protein gives your muscle both the raw material and the signal to hold its ground. Research by Longland and colleagues showed that eating more protein during a calorie deficit, paired with training, protected muscle better than eating less.15 This matters even more on a GLP-1. When your appetite drops, it’s easy to under-eat protein without noticing, you’re simply not hungry enough to go looking for it. So being deliberate about protein counts for more when your appetite is suppressed, not less.
I’ve written a full physiotherapist’s guide to this, the practical how-to of protecting muscle during weight loss, but the headline is simple. The medication handles your appetite. Strength training and protein handle your muscle. They work together, not against each other.
The Bottom Line on GLP-1 Muscle Loss
After walking through the evidence, here’s where I land as a physiotherapist. GLP-1 medications work through an elegant, well-mapped mechanism, press the doorbell, trigger the cAMP loudspeaker, quiet the brain’s hunger signals, and they produce weight loss unlike anything obesity medicine had before. That weight loss, like all weight loss, takes some muscle along with the fat. The reported amount varies widely, and some of it isn’t permanent muscle, but it’s real enough to take seriously.
So what should you do with that? Don’t panic, but don’t ignore it either. The GLP-1 muscle loss question has a clear, evidence-based answer. Strength training and enough protein genuinely help protect muscle while you lose weight, and body-composition tracking shows you whether it’s working. If you’re considering a GLP-1, or already taking one, the smartest way to frame it isn’t “the drug versus my muscle.” It’s “the drug handles appetite, and I handle the rest.” Do both, and you’re using these medications the way the evidence says they work best.
As always: this is educational information, not medical advice, and any decision about GLP-1 medication belongs between you and a qualified clinician who knows your history.
- Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes, mechanisms and clinical use. (Review of incretin pharmacology and DPP-4 resistance.)
- Frías JP, et al. Tirzepatide as a dual GIP and GLP-1 receptor agonist: mechanism and biased signalling. ScienceDirect, GLP-1/GIP receptor review, 2022.
- Nauck & Meier; Holst JJ. GLP-1 receptor signalling in beta cells: cAMP, PKA and Epac2 pathways. ScienceDirect S0196978122000158.
- GLP-1 receptor signalling and β-cell glucose metabolism. PMC5454020.
- Glucose-dependence of GLP-1-mediated insulin secretion (safety mechanism). Beta-cell signalling reviews, as above.
- Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons; DVC as entry point. Cell Metabolism, 2025.
- GLP-1R agonists activate human POMC neurons (human stem-cell-derived hypothalamic neurons). Preprint, 2024.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989 to 1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205 to 216.
- SURMOUNT-5: head-to-head tirzepatide vs semaglutide. N Engl J Med. 2025.
- Prado CM, et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024.
- Ravussin E, Bogardus C. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Appl Physiol. 1989;66(3). PMID:2243122.
- Wilding JPH, et al. Weight regain after semaglutide withdrawal (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553 to 1564; and SURMOUNT-4 (tirzepatide), 2024.
- Villareal DT, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017.
- Longland TM, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise. Am J Clin Nutr. 2016.
This article is for educational purposes only and does not constitute medical advice. It does not recommend or endorse any specific medication, and it is not sponsored. Decisions about GLP-1 therapy or any medication should be made with a qualified healthcare professional who knows your individual medical history. Figures cited are drawn from the referenced primary literature.